Timothy McAlindon to Patient Reported Outcome Measures
This is a "connection" page, showing publications Timothy McAlindon has written about Patient Reported Outcome Measures.
Connection Strength
1.300
-
Yazici Y, Tambiah JRS, Swearingen CJ, Britt J, Kennedy S, Fineman MS, Simsek I, Solomon E, McAlindon TE. A Phase 3, 56-week, randomised, double-blind, placebo-controlled study (OA-11) utilising patient-reported and radiographic outcomes evaluating the efficacy and safety of a lorecivivint injection in patients with moderate to severe knee osteoarthritis. Clin Exp Rheumatol. 2025 May; 43(5):854-860.
Score: 0.861
-
Kasturi S, Wong JB, Mandl LA, McAlindon TE, LeClair A. "Unspoken Questions": A Qualitative Study of Rheumatologists' Perspectives on the Clinical Implementation of Patient-reported Outcome Measures. J Rheumatol. 2020 12 01; 47(12):1822-1830.
Score: 0.157
-
Kasturi S, Price LL, LeClair A, Patel N, Shetty S, Sheira D, Weber S, Curtis D, Nowell WB, Salmon J, Terrin N, McAlindon TE, Mandl LA. Clinical integration of patient-reported outcome measures to enhance the care of patients with SLE: a multi-centre prospective cohort study. Rheumatology (Oxford). 2022 11 28; 61(12):4763-4774.
Score: 0.046
-
Tambiah JRS, Simsek I, Swearingen CJ, Kennedy S, Cole BJ, McAlindon TE, Yazici Y. Comparing Patient-Reported Outcomes From Sham and Saline-Based Placebo Injections for Knee Osteoarthritis: Data From a Randomized Clinical Trial of Lorecivivint. Am J Sports Med. 2022 Mar; 50(3):630-636.
Score: 0.044
-
Kasturi S, Price LL, Paushkin V, Salmon JE, McAlindon TE, Mandl LA. Impact of the first wave of the COVID-19 pandemic on systemic lupus erythematosus patients: Results from a multi-center prospective cohort. Lupus. 2021 Oct; 30(11):1747-1755.
Score: 0.042
-
Yazici Y, McAlindon TE, Gibofsky A, Lane NE, Lattermann C, Skrepnik N, Swearingen CJ, Simsek I, Ghandehari H, DiFrancesco A, Gibbs J, Tambiah JRS, Hochberg MC. A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis. Osteoarthritis Cartilage. 2021 05; 29(5):654-666.
Score: 0.041
-
Jin X, Antony B, Wang X, Persson MS, McAlindon T, Arden NK, Srivastava S, Srivastava R, Van Middelkoop M, Bierma-Zeinstra SM, Zhang W, Cicuttini F, Ding C. Effect of vitamin D supplementation on pain and physical function in patients with knee osteoarthritis (OA): an OA Trial Bank protocol for a systematic review and individual patient data (IPD) meta-analysis. BMJ Open. 2020 04 23; 10(4):e035302.
Score: 0.039
-
Lo GH, Song J, McAlindon TE, Hawker GA, Driban JB, Price LL, Eaton CB, Hochberg MC, Jackson RD, Kwoh CK, Nevitt MC, Dunlop DD. Validation of a new symptom outcome for knee osteoarthritis: the Ambulation Adjusted Score for Knee pain. Clin Rheumatol. 2019 Mar; 38(3):851-858.
Score: 0.035
-
Liu SH, Dub? CE, Eaton CB, Driban JB, McAlindon TE, Lapane KL. Longterm Effectiveness of Intraarticular Injections on Patient-reported Symptoms in Knee Osteoarthritis. J Rheumatol. 2018 08; 45(9):1316-1324.
Score: 0.034